Plain-English translation of NCT05010122 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of three medications — (taken together), , and — to treat acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in people who have a specific genetic mutation called FLT3. The trial is being run in two stages: first, doctors will figure out the safest dose of these three medications together (Phase I), and then they will test how well the treatment works at that dose (Phase II).
People with FLT3-mutated blood cancers have very limited treatment options and often do not respond well to standard therapies. This trial exists to see whether combining three medications that work in different ways might be more effective for this group of patients.
You likely qualify if…
You likely don't qualify if…
You will take three oral medications — some every day for 28 days, and some on a rotating schedule — in cycles that repeat every 28 days. In the first cycle (the induction phase), you will take all three medications. In later cycles, the schedule changes slightly. If your cancer responds well, you may eventually continue on just one of the medications as maintenance therapy. The trial will last at least several months, with regular blood tests and check-ins with your doctor to monitor how you are tolerating the treatment and how your cancer is responding.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States